Conjugated linoleic acid (CLA) is a mixture of isomers of linoleic acid (C18:2 n-6), which is mostly found in the ruminant meat and dairy products. The CLA is known to have many potential health benefits, and considered a potent powerful fatty acid, which is linked to animal and human health. The present work aims to discuss the source and production, mechanism of action, and effects of CLA on humans, poultry, and ruminants by reviewing the recent studies carried out on CLA. Despite most of the recent studies indicating beneficial effects of CLA on improving body weight control parameters, its effects on reducing risk factors of cardiovascular diseases (CVD), inflammation, blood glucose, and insulin are still controversial, and need to be further studied in different hosts.
Introduction and background
Conjugated linoleic acid (CLA), which is a mixture of positional and geometric isomers of linoleic acid (LA) or octadecadienoic acid with conjugated double bonds, has been reported to be involved in animal and human health. It is mostly found in the dairy products like raw milk derived from ruminants, but cannot be produced by the human body. The amount of CLA in the human body seems to be directly related to the dietary intake of CLA (Jiang et al., 1999) . Interest in CLA comes from late 80s when Professor Michael W. Pariza, from the University of Wisconsin, discovered a chemical form of LA, as an isolated agent in fried hamburger, which caused a reduction in the incidence of cancer in mice. Later, his team called it conjugated linoleic acid (Pariza and Hargraves, 1985; Ha et al., 1987) . The CLA is known to have many potential health benefits, such as reducing body fat deposits, improving immune function, and preventing asthma, cardiovascular diseases (CVD), high blood pressure, high cholesterol and triglycerides, osteoporosis, insulin resistance, inflammation and different types of cancer. However, recently, some adverse effects of CLA have also been reported, which are related to the effects of CLA on oxidative processes, eicosanoid production, and carcinogenesis. These effects are mostly observed in mice and with the t10, c12 isomer, and not c9,t11 isomer or the mixture of both isomers . In animal models, CLA, especially t10,c12 isomer, has been reported to have some pro-carcinogenic effects for some cancers, such as colon and prostate cancer, and it can increase prostaglandin production in cells .
In 2000, Pariza et al. discussed possible biochemical mechanisms for CLA physiological effects in their excellent review. Although the mechanisms of physiological actions of CLA are not fully clear yet, two possible mechanisms have been suggested. Firstly, CLA can reduce production of eicosanoids by decreasing the amounts of arachidonic acid (C20:4 n-6). Since eicosanoids are involved in cytokine production and in turn in inflammation effects, CLA is considered as an anti-inflammatory and anti-cancer agent (Pariza et al., 2000; Belury, 2002) . Secondly, CLA can regulate the expression of genes involved in the apoptosis induction in the cells, and also lipid oxidation, adipocyte differentiation, energy balance, and atherogenesis (Pariza et al., 2000; Belury, 2002) .
It has been reported that a total of 54 isomers of CLA possibly occur (Delmonte et al., 2004) , but only about 20 of them have been identified (Bernas et al., 2002) and the c9,t11 and t10,c12 isomers are reported to be the most abundant and bioactive CLA isomers (Pariza et al., 2001) . Between these two isomers, c9,t11-octadecadienoic acid is known to be more characterized in terms of its effects on certain health conditions, especially related to arachidonic acid metabolism (Rosberg-Cody et al., 2007) , and it is also incorporated into the phospholipids of cell membranes (Ip et al., 1994) . The t10, c12 has also been considered as an important bioactive agent (Pariza, 2004; Soel et al., 2007) . It is known as the most potent isomer of CLA for prevention of cell proliferation, a causal agent for apoptosis induction in cancer cells Ochoa et al., 2004; Cho et al., 2005; Cho et al., 2006; Lee et al., 2006) and a factor responsible for lowering of body fat Production of CLA Production of CLA can be through traditional organic synthesis, which usually results in a mixture of different CLA isomers. For example, the CLA, which is synthesized by alkali isomerization of LA and is commercially available in the market, contains four isomers (c8,t10-, c9,t11-, c10,t12-, and c11,t13-18:2) of CLA (Sehat et al., 1998) . The CLA can also be produced by microbial fermentation of LA using linoleic acid isomerase (LAI) enzyme, which results in a greater specificity of the produced isomers (Irmak et al., 2006) . For example, it is reported that many strains of lactic acid bacteria (LAB), especially the genus Lactobacillus, produce the c9,t11 isomer of CLA as a major end product of the LAI activity (Kishino et al., 2011) . However, some of this isomer can be further converted to the t9,t11 CLA isomer (Coakley et al., 2006) . Bacterial strains belonging to LAB, such as Lactobacillus and Enterococcus, and also Bifidobacterium genera have been reported to produce CLA in either synthetic media or milk with a strain-specific profile (Sieber et al., 2004) . The first report on the detection of CLA in Lactobacillus strains was by Fairbank et al. (1988) . After that, many researchers investigated the formation of CLA through common LAB, and found that although many of the tested strains were not able to produce CLA, many others belonging to lactobacilli, lactococci, and streptococci were able to convert LA to CLA in the growth medium or in skim or whole milk (Jiang et al., 1998; Lin et al., 1999; Ham et al., 2002; Kishino et al., 2002; Alonso et al., 2003; Rodr ıguez-Alcal a et al., 2011) . Hence, production of CLA using LAB and other microbial strains containing LAI could be a good alternative for organic synthesis of CLA toward producing more specified isomers. Since LAB, especially Lactobacillus strains, are most commonly used as probiotics (Shokryazdan et al., 2014a (Shokryazdan et al., , 2014b and as fermentative factors for fermentation of dairy products (Beena Divya et al., 2012) , the use of lactic acid bacterial strains, which are able to produce CLA from LA, as probiotic supplements or starter for fermentation of dairy products has been considered as an opportunity to increase the nutritional value of dairy products.
Many studies worked on the production of CLA in microorganisms, especially LAB strains. For example, Jiang et al. (1998) evaluated the ability of CLA production from free LA of 19 Figure 1 . Chemical structure of the parent linoleic acid, and its two main derivative isomers, c9,t11 and t10,c12 conjugated linoleic acids. The structures were constructed using the ChemBio3D software, version 14.0 from CambridgeSoft. different strains of lactobacilli, lactococci, streptococci, and propionibacteria, which were commonly used as dairy starter strains. Among the tested strains, two strains of Propionibacterium freudenreichii subsp. freudenreichii and one strain of P. freudenreichii subsp. sheramnii were able to convert LA into CLA with a maximum amount of 265 mg CLA/mL medium. The c-and t-9,11-octadecadienoic acid formed more than 70% of the total produced CLA. None of the tested LAB in their study was able to produce CLA. Lin et al. (1999) studied six lactic acid bacterial strains (including L. acidophilus, L. delbrueckii subsp. bulgaricus, L. delbrueckii subsp. lactis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis, and Streptococcus salivarius subsp. thermophlius) for their ability to produce CLA by adding LA in their growth media at different incubation times. They concluded that addition of LA from 1000 to 5000 mg/mL medium and increasing the incubation time from 24 to 48 hours did not affect the CLA production. Among the tested strains, L. acidophilus in 1000 mg LA/mL of skim milk added-medium incubated for 24 hours showed the highest amounts of CLA production. Ham et al. (2002) investigated CLA production of 34 LAB, isolated from human baby feces samples. Among the tested strains, only one culture of L. fermentum showed amounts of CLA, which were detectable by HPLC analysis. Alonso et al. (2003) tested four different cultures of Lactobacillus including two strains of L. acidophilus and two strains of L. casei for their CLA production from LA in MRS broth supplemented with LA. They reported a maximum range of CLA production at 80.14-131.63 mg/mL. In another study, Coakley et al. (2003) also assessed different strains of Lactobacillus, Lactococcus, Pediococcus, and Bifidobacterium for their ability to convert free LA to CLA. They found that nine strains of Bifidobacterium converted free LA to isomer c9,t11 of CLA. In their study, B. breve was able to convert up to 65% of LA to c9,t11 of CLA. The t9,t11 isomer of CLA was also produced by some of the strains at low amounts. Rodr ıguez-Alcal a et al. (2011) tested 22 probiotic bacteria for their CLA production ability. Among the tested strains, they selected two strains belonging to Bifidobacterium, two Lactobacillus strains, and one Lactococcus strains based on their CLA production ability, with LA as substrate. They determined the amounts of produced CLA to be in the range of 40 to 50 mg CLA/mL medium. They identified the produced CLA isomers to be in the following order: C18:2 c9,t11 (60-65%) > C18:2 t10,c12 (30-32%) > C18:2 t9,t11 and C18:2 t10,t12 (2-5%).
Mechanisms of CLA production
So far, two groups of enzymes introducing conjugated double bonds in fatty acids are known. These groups are the special desaturases or conjugases, which are mainly responsible for conversion of LA into linolenic acid isomers containing three conjugated double bonds and the polyenoic fatty acid isomerases (PAI), which have been reported from Butyrivibrio fibrisolvens (Kepler et al., 1966) . The LAI is included in the second group (Hornung et al., 2005) . The activity of LAI, the catalyzing enzyme for conversion of LA into CLA, has first been described by Tove's team for production of c9,t11 isomer from LA by B. fibrisolvens (Kepler et al., 1966) , a rumen bacteria involved in the biohydrogenation process (Kepler and Tove, 1967) . They explained that first LA is rapidly converted to c9,t11 CLA by LAI of the rumen bacteria, and after that c9,t11 CLA is converted to C 18:1,t11 vaccenic acid by a slower rate (Kepler et al., 1966; Kepler and Tove, 1967) . To complete the biohydrogenation process of LA, vaccenic acid is then reduced to form stearic acid as the end product. Fig. 2 shows the biochemical pathway for biohydrogenation of LA by rumen microorganisms. Vaccenic acid has also been reported to be transformed into c9,t11 CLA in the mammary glands by the delta-9 desaturase enzyme. This is considered as the second mechanism for the presence of c9,t11 CLA in milk fat Coakley et al., 2003) . In 2001, Ogawa et al. explained a mechanism of CLA production from LA and suggested that presence of LA in the growth medium of microorganisms induced the enzyme system for CLA production. Based on their report, the conversion of LA to CLA involved the production of hydroxy fatty acids (10-hydroxy-t-12-octadecaenoic acid and 10-hydroxy-c-12-octadecaenoic acid) as intermediate factors (Ogawa et al., 2001) . They used washed cells of L. acidophilus AKU 1137 to produce CLA from LA in microaerobic conditions, and reported a conversion of over 95% of added LA in the growth medium to CLA, which caused the concentration of CLA to be more than 80% (w/w) of total fatty acids. Fig. 3 presents their proposed pathway of CLA production from LA using washed cells of L. acidophilus AKU 1137.
Enzyme purification for production of CLA
Purification of LAI from microorganisms and using it for manufacturing CLA is another possible way to produce considerable amounts of CLA. To date, three LAI from Lactobacillus reuteri (producing c9,t11 CLA), Clostridium sporogenes (producing c9,t11 CLA), and Propionibacterium acnes (producing t10,c12 CLA) have been fully characterized . The LAI has been found in two forms of soluble enzyme and as a membrane-bound protein. In terms of using purified LAI enzyme to produce CLA, the soluble form of LAI from P. acnes has been intensely studied because of its stability and ease of purification (Hornung et al., 2005; Rosberg-Cody et al., 2007) . However, the P. acnes is a pathogenic strain for human and its usage for fermentation of foods and dairy products is impossible. On the other hand, the LAI is presented in LAB in a membrane-associated form, and produces the c9,t11 isomer of CLA as the main product (Irmak et al., 2006; Macouzet et al., 2010) . Hence, LAB containing LAI have been considered as good candidates to be used as starters for fermentation of dairy products or as probiotic supplements for humans and/or animals to take advantage of the produced CLA. However, the LAI of LAB is unstable during its recovery in a soluble form making it difficult to be studied (Irmak et al., 2006) .
Biotechnological techniques in microbial production of CLA
Nowadays, new biotechnological techniques can be used to obtain transformed microbial strains that are able to produce higher amounts of CLA than the ordinary existing strains (Irmak et al., 2006) . Some studies employed genetic engineering of microorganisms to enhance CLA production. For example, the LAI derived from P. acnes has been expressed in Saccharomyces cerevisiae (Hornung et al., 2005) , E. coli, and Lactococcus lactis (Rosberg-Cody et al., 2007) to produce CLA by the transformed organisms. Hornung et al. (2005) expressed PAI from P. acnes in E. coli and characterized it biochemically. This enzyme catalyzes the isomerization of a methylene-interrupted double bond to a conjugated double bond, resulting in the 10E,12Z isomer of CLA from a wide range of free polyunsaturated fatty acids (PUFA) as substrates. Rosberg-Cody et al. (2007) cloned and overexpressed the LAI from P. acnes into Lactococcus lactis and E. coli. They found between 30 and 50% conversion rates of LA to t10,c12 CLA. Zhang et al. (2012) expressed the LAI gene from P. acnes into Yarrowia lipolytica Polh improving the expression of the enzyme in Yarrowia lipolytica by codon usage optimization and multi-copy integration. They found that the yeast containing the codon-optimized gene produced six times higher amounts of t10,c12 CLA than the yeast containing the native gene, which increased to about 30 times higher by a combination of multi-copy integration. In another study, the same microorganism (Y. lipolytica) was used to enhance its production of CLA by using co-expression of the delta 12-desaturase gene from Mortierella alpina together with the codon-optimized LAI gene that enhanced the production of CLA by the transformed Y. lipolytica (Zhang et al., 2013) .
CLA in ruminants
The CLA has been studied intensively in ruminants. Some studies investigated the CLA content of ruminant milk fat and meat, and some others evaluated other effects of CLA on ruminants, such as effects of CLA on milk production and composition, and also on metabolic key parameters of blood, lipid metabolism, inflammation, etc., which will be discussed in the following subsections. However, most of the studies on CLA in ruminants focused on milk fat.
Concentration of CLA in ruminant meat
The c9,t11 isomer of CLA is the predominant isomer in both meat and milk of ruminants, but its concentration in meat is less than that in milk of ruminants. It may be related to effects of the diet, so that for cattle that received a traditional high-concentrate, low-fiber diets in the United States, the concentration of c9,t11 isomer of CLA in their meat was lower when compared with that of milk . However, the same isomer constituted more than 90% of the total CLA in subcutaneous and intramuscular fat of German Simmental cattle, which received corn-silage-based diets with a moderate level of grain supplement (Fritsche and Fritsche, 1998) . It is important to note that the content of CLA from ruminant meat is largely dependent on the concentration of CLA in the raw products because CLA is relatively stable during processing and storage.
Concentration of CLA in ruminant milk fat
It is believed that grazing, in comparison to intensive husbandry, increased the amounts of CLA in milk fat. For example, Tsiplakou et al. (2006) who investigated the CLA content of milk fat of grazing sheep and goats found that the CLA concentration of sheep milk fat was much higher than that of goats, with a negative correlation between sheep milk fat and its CLA content. Pajor et al. (2009) who evaluated the effects of grazing on the fatty acid profile of goat milk and cheese reported that grazing considerably increased the total CLA content in milk (0.59 vs. 0.77%) and cheese (0.52 vs. 0.84%) of the grazing goats compared to the control group, which were kept indoors. Tudisco et al. (2014) who evaluated the effect of pasture on the fatty acid profile of goat milk reported that goats on pasture showed higher amounts of CLA in their milk in comparison with the control animals.
Effects of CLA on milk fat
It is well documented that although dietary supplementation of CLA for dairy ruminants can increase the amounts of CLA in their milk, CLA has a reducing effect on milk fat of dairy ruminants, especially cows and sheep , which has been mostly attributed to a decrease in biosynthesis of lipids. For example, in a study by Vyas et al. (2013) , abomasal infusion of CLA reduced de novo synthesized fatty acid concentration in dairy cows. Perfield et al. (2007) who investigated the effect of CLA on milk fat of cows reported that the increase in t9,c11 CLA corresponded to a decrease in milk fat yield. The t10,c12 CLA also decreased de novo synthesized fatty acids and desaturation of 18:0 via D9-desaturase. However, t9,t11 CLA had no effect on milk fat yield.
In addition, the t10,c12 isomer of CLA has been reported to decrease milk fat in both ruminants and non-ruminants . Three studies on lactating sheep showed that t10,c12 CLA supplementation reduced milk fat production like that observed in dairy cows (Lock et al., 2006; Sinclair et al., 2007; Lock et al., 2008) . Hussein et al. (2013) also reported that the effect of CLA on milk fat depression is associated with less expression of mammary genes involved in lipid synthesis in dairy ewes. In their study, CLA reduced the milk fat percentage and milk fat yield by about 23%. Lock et al. (2008) also reported a reduction in milk fat of lactating goats by supplementation of a lipid-encapsulated t10,c12 CLA. In their study, although CLA supplementation at 30 and 60 g/d CLA did not affect milk yield, milk protein yield, and dry matter intake of the goats, it reduced milk fat yield by 8 and 21%, respectively. This reduction in milk fat yield was attributed to reduction in both de novo fatty acid synthesis and uptake of offered fatty acids. They concluded that t10,c12 CLA decreased milk fat synthesis in dairy goats like that observed for dairy cows and sheep, but the reduction was lesser for goats compared to cows and sheep. In contrast, some other studies on goats reported that t10,cis12 CLA had no effect or trace effect on milk fat yield (Erasmus et al., 2004; Schmidely and Morand-Fehr, 2004; De Andrade and Schmidely, 2006) . As mentioned earlier, the t10,c12 isomer of CLA has been reported to also reduce milk fat in non-ruminants . For example, exogenous t10,c12 CLA decreased lipid synthesis in murine adipose and mammary tissues (Kadegowda et al., 2013) . They showed that by supplementing with 37 mg CLA/d, the milk fat concentration of the mice was 44% lower on day 10 postpartum compared to day 6 postpartum, and concluded that CLA affected the mammary tissues mostly by alterations in cellular signaling pathways and phospholipid biosynthesis (Kadegowda et al., 2013) .
Other aspects of CLA effects on ruminants
Effects of CLA on ruminants are not limited to milk production and composition. Other effects on metabolic key parameters of blood, lipid metabolism, inflammation, etc. have also been investigated. Sigl et al. (2010) fed a CLA (50% c9,t11 and 50% t10,c12 CLA) supplemented diet to dairy cows in their first lactation month. They detected higher amounts of CLA in the milk fat of CLA-supplemented cows in comparison with the control group. They also detected a reduction in saturated fatty acids (SFA) of milk fat with an increase in monounsaturated and trans SFA in cows that received CLA. However, CLA did not have any significant effects on milk yield and composition, metabolic key parameters of blood, or gene expression of peroxisome proliferator-activated receptor (PPAR)-a, PPAR-g, sterol regulatory element-binding protein-1, and tumor necrosis factor-alpha (TNF-a) in liver tissues. Schlegel et al. (2012) who fed cows with a rumen-protected CLA (c9,t11 and t10, c12) fat to investigate its effect on milk and hepatic lipid metabolism of the animals at fifth week of lactation reported that while total milk yield increased, milk fat yield and content decreased, and energy balance improved. The regulation of 107 genes involved in hepatic lipid metabolism and expression of key enzymes of lipogenesis, b-oxidation, and ketogenesis, as well as concentrations of triacylglycerols and cholesterol in liver and plasma, were not affected by CLA. Saremi et al. (2012) investigated potential anti-inflammatory effects of long-term supplementation of CLA in cows using the haptoglobin assessment. Although the CLA showed no anti-inflammatory effects on serum Hp and liver Hp mRNA, the CLA showed antiinflammatory effects on Hp in omental and subcutaneous fat, indicating its tissue-specific effects. Kramer et al. (2013) investigated the effect of feeding a diet supplemented with a rumenprotected CLA containing c9,t11 and t10,c12 CLA on fatty acid distribution of lipids in several body tissues compared to their distribution in milk fat in early lactating heifers. They reported a milk fat depression by a reduction of de novo synthesis of fatty acids without any considerable effect on tissue lipids. Higher amounts of fed CLA isomers were detected in the milk fat of cows receiving CLA than the control animals. The distribution of fatty acids in mammary glands was similar to that of the milk fat; however, it was mainly because of residual of milk in the mammary gland, not influencing of gene expression. Fatty acids of the liver did not show any differences except for an increase in trans-octadecenoic acids. Adipose tissue and longissimus were only marginally affected by the CLA supplementation.
CLA in poultry
Unlike ruminants, dietary fatty acids do not undergo changes before absorption in birds. Therefore, CLA supplementation of the diet is a widely used strategy to increase the CLA content of the tissues in poultry (Du and Ahn, 2002; Sirri et al., 2003; Royan et al., 2013) . Many studies on the effects of dietary CLA on poultry mostly focused on the performance, lipid metabolism, and immune system.
Effects of CLA on poultry performance
Studies have shown that CLA can affect the performance of broilers where the growth rate is more sensitive to CLA than other performance traits, so that the dietary CLA levels higher than 1% (10 g/kg) decreased the growth rate of broilers (Szymczyk et al., 2001; Badinga et al., 2003) . However, results of different studies on the effects of CLA on weight gain of chickens have been inconsistent. A linear increase of daily weight gain (Thiel-Cooper et al., 2001) , moderate weight loss (Cook et al., 1993) , and adverse effects on weight gain using up to 1.5% CLA supplementation (Suksombat et al., 2007) and 1% CLA (Buccioni et al., 2009 ) have been reported. Royan et al. (2011b) changed the CLA dose, bird age, and fat composition of the diet so that chicks fed diets containing a lower CLA level in the 445 finisher phases showed an acceptable body weight gain compared to those receiving higher CLA levels. They reported that the adverse effects of CLA on body weight gain of chickens is dose related, so that broilers fed a high dietary CLA dose (4.2%) had lower weight gains than those fed diets containing 2.1% CLA. Many studies reported no adverse effect on feed intake by incorporating different CLA levels in the diet (Szymczyk et al., 2001; Du and Ahn, 2003; Sirri et al., 2003; Takahashi et al., 2003; Denli et al., 2004; Bolukbasi, 2006; Suksombat et al., 2007; Buccioni et al., 2009 ). Du and Ahn (2002) showed that although up to 1% dietary CLA had no effect on feed consumption of broilers, 2 or 3% CLA reduced feed consumption. Javadi et al. (2007) reported that 1% dietary CLA was enough to show adverse effects on broiler feed intake. On the other hand, one occasional positive effect of CLA on feed intake has been reported by Bolukbasi (2006) where there was an increased feed intake in broiler chickens fed diets containing 1% CLA compared with the control group with no difference shown between dietary supplementation of 2 or 3% CLA and the control diet. Some other studies have shown that the ability of chickens to use CLA is increased with age. It means that although CLA may reduce the feed intake of the birds in the starter or grower phases of the rearing period, it recovered later in the finisher phase (Suksombat et al., 2007; Royan et al., 2011b) . The reported effects of CLA on feed conversion ratio (FCR) of chickens are also controversial, which included unfavorable increased FCR (Royan et al., 2011b ), no effect on FCR (Szymczyk et al., 2001; Du and Ahn, 2002; Javadi et al., 2007) , and reduced FCR (Bolukbasi, 2006) .
A meta-analysis study by Cho et al. (2013) on the effects of CLA feeding on growth performance and fatty acid profile of chicken meat revealed that CLA does not have beneficial effects on growth performance, but may be effective in modulating n-6/n-3 fatty acid ratios in the thigh meat. Adverse effects have also been observed on the performance of layer hens following CLA addition to the diet. Szymczyk and Pisulewski (2003) reported a reduced feed intake and egg mass when using CLAenriched diets for layer hens.
Effects of CLA on poultry lipid metabolism
Reduction of carcass fatness and mainly abdominal fat pad is a goal of the poultry industry, which can be achieved by CLA supplementation in the diet. However, reports on the effects of CLA on abdominal fat pad alteration are conflicting. Some studies showed that diets containing CLA increased the abdominal fat pad content in chickens (Du and Ahn, 2002; Javadi et al., 2007) , while others showed a reduction (Szymczyk et al., 2001; Badinga et al., 2003) . Buccioni et al. (2009) found positive effects of CLA (1%) on the carcass yield, and claimed that these effects were related to the significant decrease in abdominal fat pad and were attributed to the ability of CLA to reduce body fat accumulation. On the other hand, Suksombat et al. (2007) reported that the reduced abdominal fat pad in birds fed dietary CLA was not accompanied by any increase in carcass, breast, or thigh composition. Royan et al. (2011a) confirmed the reduction in abdominal fat by a downregulation of PPAR-g mRNA expression in the abdominal adipose tissue. The PPAR-g is the most important transcription factor that regulates lipid metabolism and adipocyte differentiation, and is strongly associated with the abdominal fat deposition in avian species (Sato et al., 2009; Xiong et al., 2010) . Royan et al. (2011b) showed that dietary CLA, through the effect on PPAR-g, also reduced the fat content of the breast muscle in broiler chickens. Kawahara et al. (2009) reported that feeding broilers with 1-2% CLA in the diet reduced the total lipid and triglyceride concentration in breast meat. An increase in liver weight in CLA fed chicken has also been reported (Du and Ahn, 2002; Badinga et al., 2003; Suksombat et al., 2007; Royan et al., 2011b) . Based on animal studies, the incidence of fatty liver is the most important concern related to CLA consumption (Pariza, 2004) . Fatty livers may occur due to the CLA effects on body fat mobilization as well as an increased fatty acid synthesis in the liver (Tsuboyama-Kasaoka et al., 2000; Cl ement et al., 2002; Yanagita et al., 2005) .
Increased plasma triglyceride concentration in broiler chickens has been observed following CLA administration (Du and Ahn, 2003) . This may be due to alterations in activities of enzymes involved in hepatic lipid metabolism. Avian lipid synthesis takes place mainly in the liver, with the adipose tissue as the lipid storage organ. Park et al. (1997) attributed this CLA enhancing effects on serum triglycerides as a result of the simultaneous inhibitory role of CLA on lipoprotein lipase and stimulation of lipolysis in the adipose tissue. Hence a reduction in fat deposits and increased lipolysis in adipocytes could be the reasons for the elevated serum triglyceride levels observed in broiler chickens. Du and Ahn (2003) confirmed that dietary CLA increased the liver fatty acid synthase enzyme, one of the main enzymes regulating fatty acid synthesis. Therefore, the increased plasma triglyceride levels could be due to the higher liver fatty acid synthase activity. Total cholesterol and LDL cholesterol coordinated changes (Bhattacharya et al., 2006; Feitoza et al., 2009) and an increase in serum HDL level (Du and Ahn, 2003; Bolukbasi, 2006) have also been reported in birds fed CLA.
Effects of CLA on poultry immune system
The CLA can beneficially stimulate the immune response in broiler chickens (Zhang et al., 2005) . Dietary CLA induced anti-sheep red blood cell (SRBC) antibody production in broilers (Takahashi et al., 2003) . Long et al. (2011) reported the CLA enhancing role in chickens, particularly during the Infectious Bursal Disease Virus (IBDV)-immunosuppressive status. They attributed the immunoregulatory functions of CLA on broiler chickens mainly to the anti-inflammatory effects of CLA that were mediated by suppressing the IBDV-specific proinflammatory cytokine mRNA relative expression.
Investigation of immunoregulatory actions of CLA by Long et al. (2012) showed that CLA alleviated the immunosuppression of T lymphocytes in broiler chickens exposed to cyclosporin A by increasing peripheral blood T lymphocyte proliferation and interleukin-2 levels.
CLA in humans
Many researchers have investigated various effects of CLA in humans, mostly focusing on the effects of CLA on serum glucose, insulin resistance, body weight control, serum cholesterol and triglycerides, CVD, inflammation, and blood pressure. Table 1 summarizes the results of recent studies on the effects of CLA in humans.
Effects of CLA on serum glucose and insulin sensitivity
Studies on the effects of CLA on serum glucose and insulin showed conflicting findings for different subjects. Moloney et al. (2004) , who investigated the effects of CLA (a mixture of c9,t11 and t10,c12 isomers) consumption on markers of glucose and insulin metabolism in patients with type II diabetes, reported that the CLA had an adverse effect on insulin and glucose metabolism by increasing the fasting glucose concentrations and reducing insulin sensitivity. Thrush et al. (2007) also reported that CLA consumption caused a reduction in insulin sensitivity in overweight, non-diabetic subjects. However, Tricon et al. (2006) , who studied the effects of dairy products enriched with c9,t11 CLA (and t11-18:1) on insulin resistance in healthy men, reported that CLA had no effect on serum insulin and glucose. Racine et al. (2010) showed that CLA did not have any significant effect on plasma glucose and insulin of 6-to 10-year-old obese children. However, Colakoglu et al. (2006) reported a reduction in the concentrations of serum glucose and insulin in healthy female young subjects that received CLA supplementation, combined with aerobic exercise.
Effects of CLA on lipid metabolism and body weight control
Like the effects of CLA on serum glucose and insulin resistance, results of studies on the effects of CLA on lipid metabolism and body weight control were also conflicting. Some studies reported positive and improving effects of CLA consumption on lipid metabolism and body weight. For instance, Gaullier et al. (2005) investigated the effects of long-term (24 months) CLA consumption on body composition, body weight, body mass index (BMI), and serum lipids, and the results showed no changes in HDL cholesterol and triglycerides of plasma although total cholesterol and low density lipoprotein (LDL) cholesterol decreased. They reported that CLA decreases body fat mass (BFM) in overweight subjects, thus helping maintain initial reductions in BFM and weight in the long-term periods. Chen et al. (2012) also reported that a 12-week supplementation of CLA in overweight subjects caused lower obesity indices, with no obvious adverse effects. In addition, Colakoglu et al. (2006) showed that CLA supplementation combined with aerobic exercise improved the body composition of healthy female young subjects. Besides, in the study by Racine et al. (2010) on the effects of CLA (a mixture of c9,t11 and t10,c12 isomers) on fat and BMI in 6-to 10-year-old obese children, the CLA attenuated an increase of BMI and also decreased body fatness compared to the control group. The CLA did not have any significant effect on LDL cholesterol in these children, but it reduced HDL cholesterol significantly. Pfeuffer et al. (2011) showed that, in comparison with safflower oil, consumption of CLA decreased body weight without changing parameters associated with a metabolic syndrome, such as total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
Some studies reported that CLA had no effect on lipid metabolism and body weight. For example, Tricon et al. (2006) showed that consumption of dairy products enriched with c9, t11 CLA (and t11-18:1) had no effect on body weight, triacylglycerols, total cholesterol, and LDL and HDL cholesterol. Nazare et al. (2007) , who studied the effects of CLA supplementation (a mixture of c9,t11 and t10,c12) in yogurt-like dairy products on body composition and the expression of several key adipose tissue genes [PPAR-g, lipoprotein lipase (LPL), hormone-sensitive lipase (HSL), and uncoupling protein 2 (UCP-2)], observed no significant effects on body weight, fat mass, or free fat mass of healthy subjects, although the basal energy expenditure increased. The mRNA expression of PPARg was increased, but mRNA levels of HSL were decreased by CLA consumption. However, the amounts of mRNA for UCP-2 and LPL did not show any changes. Asp et al. (2011) , who investigated the effects of CLA on blood lipids in obese, postmenopausal women with type II diabetes, also reported that CLA did not affect the tested metabolic parameters. The study by Joseph et al. (2011) also did not support the role of CLA as an effective body weight or a blood lipid regulator. They investigated the effects of CLA (a mixture of t10,c12 and c9,t11 CLA: Clarinol G-80, and c9,t11 isomer of CLA) consumption on body composition and blood lipids in overweight, hyperlipidemic men, and showed that CLA consumption had no effect on body weight, blood lipids, b-oxidation rate of fatty acids, or other tested parameters.
Effects of CLA on inflammatory markers of CVD
Although a number of human studies reported that CLA has an anti-atherosclerotic effect on serum lipid profile (as mentioned above), most of recent studies on the inflammatory markers of CVD, especially C-reactive protein, interleukin-6 (IL-6), and TNF-a, revealed that CLA supplementation has no significant effect on the markers. For instance, in the studies on healthy men (Tricon et al., 2006) , patients with type II diabetes (Moloney et al., 2004) , healthy young men (Raff et al., 2008) , obese, post-menopausal women with type II diabetes (Asp et al., 2011) , and overweight, hyperlipidemic men (Joseph et al., 2011) , the consumption of CLA had no effect on inflammatory markers of CVD.
Effects of CLA on blood pressure
In case of blood pressure, some researchers reported that CLA had no effect on the blood pressure of healthy young men (Raff et al., 2006) , in young overweight women (Diaz et al., 2008) , or healthy volunteers (Engberink et al., 2012) . However, Pfeuffer 
Effects of CLA on cancer
To the best of our knowledge, very few studies have been carried out on the effects of CLA on the incidence of cancer in humans. Hence, the limited number of studies makes it difficult to ascertain whether CLA could protect humans against cancer. In an study on 55-to 69-year-old female subjects, a weak positive relationship between breast cancer incidence and the intake of CLA was reported (Voorrips et al., 2002) . Another study on post-menopausal women, patients with breast cancer showed lower levels of serum and dietary CLA than the control subjects (Aro et al., 2000) . However, the concentration of CLA in breast adipose tissue was not associated with the relative risk of breast cancer (Chaj es et al., 2002) .
Although the number of studies on the effect of CLA on incidence of cancer in humans is limited, this approach has been intensively studied in animal models, especially rats (Kelley et al., 2007) . Dietary supplementation of CLA inhibited chemically induced tumors of the mammary gland, skin, colon, and the forestomach in several animal models (Kelley et al., 2007) . Studies on the effects of CLA on tumors induced in the mammary gland of rats (Ip et al., 1999; Ip et al., 2002) and forestomach of mice (Chen et al., 2003) suggest that CLA had an inhibiting effect on the tumor yield or incidence. In addition, CLA was able to inhibit the metastatic lung tumor load of mice with induced mammary tumor, which spontaneously metastasizes to the lung (Hubbard et al., 2003) . However, results of another study, in which Min mice were fed a diet containing 1% c9,t11 or t10,c12 isomer of CLA, suggested that the t10,c12 isomer can act as a growth promoter for small intestine carcinogenesis (Rajakangas et al., 2003) .
Mechanisms involved in the inhibitory effects of CLA on different types of cancers have been reported to be related to alteration of lipid peroxidation and tissue fatty acid composition, eicosanoid metabolism, and expression of genes involved in regulating cell growth and apoptosis (Kelley et al., 2007) . Since these mechanisms of action that are associated with tumorigenetic effects of CLA are varied for different types of tumor and different stages of tumor progression, the response of different types of cancers to CLA treatments in various organs would probably be different. Hence, the comparison of the results from the studies mentioned earlier and extrapolating the results to humans may be difficult and not appropriate. Further studies with appropriate animal models, which parallel human pathogenesis, have to be carried out in order to have a more accurate assessment on the effects of CLA on cancer in humans.
Experiments on rats as a model for human physiology Zhou et al. (2008) investigated the effect of CLA on insulin resistance and its molecular mechanisms in obese rats, as a model representing human physiology. They reported that the dietary CLA supplementation decreased the body weight gain and white fat pad weight, the levels of plasma free fatty acids, triglycerides, cholesterin, leptin, insulin, and blood glucose concentration. The CLA improved insulin resistance by increasing mRNA expression of PPAR-g, and its target genes such as fatty acid binding proteins, fatty acid transporter proteins, and adiponectin in the adipose tissues of the obese rats. In another study, Rodrigues et al. (2014) used fat from goat milk naturally enriched with CLA to investigate the effects of CLA on serum lipids and glucose, body weight, and intestinal and liver histopathological parameters of male rats. They showed that CLA caused an increase in the body weight of the rats from the second to the fifth week of the experiment, indicating its growth-promoting activity in young rats. The CLA also increased the serum levels of total cholesterol and HDL cholesterol and reduced the levels of triglycerol and triglycerol/HDL cholesterol ratio with no significant effect on LDL cholesterol and serum glucose.
Conclusions
Generally, CLA is considered as a potential health-promoting factor, which has many beneficial effects on the health of humans and animals, and can prevent many health disorders. Since CLA cannot be produced by the human body, microbial functional foods and animal products containing CLA are considered as good sources of CLA for human. In ruminant husbandry grazing in comparison to indoor feeding and supplementation of CLA in the diet of animals can increase the concentration of CLA in ruminants products. In addition, microbial fermentation of dairy products can be used as an option to increase the concentration of CLA toward production of functional foods for human. In poultry industry also, CLA can be used as a dietary supplement to increase the CLA content of tissues, and also to improve performance, lipid metabolism, and the function of immune system of poultry. In case of humans, although most of the recent studies confirmed the beneficial effects of CLA such as improving the body weight control parameters in humans and inhibition of different types of cancer in animal models, the effects of CLA on serum lipid profile, blood glucose, insulin sensitivity, blood pressure and risk factors of CVD are still controversial, and need to be further investigated using different hosts with different health conditions.
